

Titolo:	A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisafoclax (APG-2575) in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)
Codice studio	GLORA-4
Patologia:	Sindrome mielodisplastica
Tipo di Studio:	Interventistico
Tipologia	Profit
Fase:	3
Principali criteri di inclusione:	<ul style="list-style-type: none"> Newly Diagnosed MDS with presence of < 20% bone marrow blasts per bone marrow biopsy/aspirate at screening, as well as with IPSS-R score >3 (intermediate, high, or very high). Subjects eligible for hematopoietic stem cell transplantation (HSCT) who are not scheduled for HSCT ; or subjects who are not eligible for HSCT.
Principali criteri di esclusione:	<ul style="list-style-type: none"> Previous diagnosis of: Therapy-related MDS (t- MDS), MDS evolving from a pre-existing myeloproliferative neoplasms (MPNs), MDS/MPN: including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML), and unclassifiable MDS/MPN MDS with advanced myelofibrosis (MF \geq grade 3), or MDS with severe autoimmune hemolysis Have received any previous anti-tumor therapy for MDS
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it